Patents by Inventor Manibarsha Goswami

Manibarsha Goswami has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11452714
    Abstract: An example composition includes a therapeutically effective amount of a histidine kinase inhibitor. The histidine kinase inhibitor includes at least one of a 6-benzo[d]thiazol-2-amine derivative, a purine derivative, an adenine derivative, an adenine-sulfonyl fluoride derivative, a riluzole analog, a riluzole-sulfonyl fluoride derivative, a 6-benzo[d]thiazol-2-amine-sulfonyl fluoride derivative, a 6,6?-oxybis(benzo[d]thiazol-2-amine) derivative, or a 6,6?-oxybis(benzo[d]thiazol-2-amine)-sulfonyl fluoride derivative. An example technique for treating a bacterial infection includes administering a composition comprising a histidine kinase inhibitor to a patient.
    Type: Grant
    Filed: May 23, 2018
    Date of Patent: September 27, 2022
    Assignee: Regents of the University of Minnesota
    Inventors: Erin E. Carlson, Manibarsha Goswami
  • Publication number: 20220091506
    Abstract: A photoresist composition comprises a first polymer comprising a first repeating unit comprising a hydroxy-aryl group and a second repeating unit comprising an acid-labile group, wherein the first polymer does not comprise a lactone group; a second polymer comprising a first repeating unit comprising a hydroxy-aryl group, a second repeating unit comprising an acid-labile group, and a third repeating unit comprising a lactone group; a photoacid generator; and a solvent.
    Type: Application
    Filed: August 31, 2021
    Publication date: March 24, 2022
    Inventors: Ke Yang, Emad Aqad, James F. Cameron, Suzanne M. Coley, Manibarsha Goswami, ChoongBong Lee, Bhooshan Popere, James W. Thackeray, Brandon Wenning
  • Publication number: 20200101048
    Abstract: An example composition includes a therapeutically effective amount of a histidine kinase inhibitor. The histidine kinase inhibitor includes at least one of a 6-benzo[d]thiazol-2-amine derivative, a purine derivative, an adenine derivative, an adenine-sulfonyl fluoride derivative, a riluzole analog, a riluzole-sulfonyl fluoride derivative, a 6-benzo[d]thiazol-2-amine-sulfonyl fluoride derivative, a 6,6?-oxybis(benzo[d]thiazol-2-amine) derivative, or a 6,6?-oxybis(benzo[d]thiazol-2-amine)-sulfonyl fluoride derivative. An example technique for treating a bacterial infection includes administering a composition comprising a histidine kinase inhibitor to a patient.
    Type: Application
    Filed: May 23, 2018
    Publication date: April 2, 2020
    Inventors: Erin E. Carlson, Manibarsha Goswami